Sanofi (SNY) Gross Margin (2009 - 2026)

Sanofi has disclosed Gross Margin across 18 years of filings, most recently posting 77.13% for Q1 2026.

• Gross Margin for Q1 2026 came in at 77.13%, down 85.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 76.98% (down 96.0% YoY), and the FY2025 annual result was 77.17%, up 151.0% from the prior year.
• Gross Margin came in at 77.13% for Q1 2026 at Sanofi, down from 81.66% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 83.31% in Q4 2024 to a low of 72.0% in Q4 2022.
• The 5-year median for Gross Margin is 76.02% (2024), against an average of 76.35%.
• Across the five-year window, Gross Margin surged 853 bps in 2024 and sank 165 bps in 2025, its largest moves.
• Sanofi's Gross Margin stood at 72.0% in 2022, then rose by 4 bps to 74.78% in 2023, then advanced by 11 bps to 83.31% in 2024, then dropped by 2 bps to 81.66% in 2025, then fell by 6 bps to 77.13% in 2026.
• The last three Gross Margin figures came in at 77.13% (Q1 2026), 81.66% (Q4 2025), and 78.02% (Q3 2025), per Business Quant data.